Loading
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Latest quote
$196.48
+$9.02 · +4.81%
After-hours
$195.89
−$0.59 · -0.30%
Oct 7, 7:59 PM ET
Regular session · ET · Market data may be delayed.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Day range
Current $196.48
52-week range
Current $196.48
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
24
Expensive
Sentiment
50
Mixed
Risk
46
Elevated Risk
Momentum
82
Strong Up
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Day range
Current $196.48
52-week range
Current $196.48
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.94B USD | 3.2B USD | 6.85B USD | 18.88B USD | 17.74B USD |
| Cost of goods sold | 868M USD | 1.46B USD | 4.69B USD | 5.42B USD | 2.62B USD |
| Gross profit | 1.08B USD | 1.74B USD | 2.16B USD | 13.46B USD | 15.12B USD |
| Research and development | 3.13B USD | 4.54B USD | 4.85B USD | 3.3B USD | 1.99B USD |
| Selling, general, and administrative | 1.02B USD | 1.17B USD | 1.55B USD | 1.13B USD | 567M USD |
| Operating expenses | 4.15B USD | 5.68B USD | 6.39B USD | 4.04B USD | 1.82B USD |
| Interest income | 314M USD | 425M USD | 421M USD | 200M USD | 18M USD |
| Interest expense | 10M USD | 24M USD | 38M USD | 29M USD | 18M USD |
| Depreciation and amortization | 215M USD | 189M USD | 621M USD | 348M USD | 232M USD |
| Operating income | −3.07B USD | −3.95B USD | −4.24B USD | 9.42B USD | 13.3B USD |
| Net income | −2.82B USD | −3.56B USD | −4.71B USD | 8.36B USD | 12.2B USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$115.7
41.11% downsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P 500 ETF1557.T133.84B0.10%129.41T JPY0.09%¥123,000-0.32%
Vanguard Morningstar Total Stock Market ETFVTI1.59B0.07%2.3T USD0.03%$381.03-0.40%
Vanguard S&P 500 ETFVOO1.32B0.07%1.8T USD0.03%$714.34-0.26%
Vanguard Morningstar Small-Cap ETFVB1.15B0.62%185.3B USD0.03%$286.98-1.41%
iShares Core S&P 500 ETFIVV927.27M0.10%899.63B USD0.03%$780.58-0.25%
State Street SPDR S&P 500 ETFSPY845.17M0.10%819.04B USD0.09%$777.22-0.24%
Vanguard Morningstar Small-Cap Value ETFVBR732.31M1.07%68.2B USD0.05%$232.17-1.32%
iShares Biotechnology ETFIBB518.07M4.98%10.4B USD0.44%$203.34+0.12%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Small-Cap ETFVBiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYVanguard Morningstar Small-Cap Value ETFVBRiShares Biotechnology ETFIBBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
